ECSP18034035A - Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico - Google Patents

Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico

Info

Publication number
ECSP18034035A
ECSP18034035A ECIEPI201834035A ECPI201834035A ECSP18034035A EC SP18034035 A ECSP18034035 A EC SP18034035A EC IEPI201834035 A ECIEPI201834035 A EC IEPI201834035A EC PI201834035 A ECPI201834035 A EC PI201834035A EC SP18034035 A ECSP18034035 A EC SP18034035A
Authority
EC
Ecuador
Prior art keywords
preparation
compounds
cryptophyin
novelty
therapeutic use
Prior art date
Application number
ECIEPI201834035A
Other languages
English (en)
Inventor
Antony Bigot
Francois Clerc
Herve Bouchard
Jidong Zhang
Marie-Priscille Brun
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP18034035A publication Critical patent/ECSP18034035A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de criptoficina de fórmula (I): (LA FORMULA SE ENCUENTRA INCORPORADA EN EL RESUMEN) La invención también se refiere a cargas útiles de criptoficina, a productos conjugados de criptoficina, a composiciones que los contienen y a su uso terapéutico, especialmente como agentes anticancerosos. La invención también se refiere al procedimiento para la preparación de estos productos conjugados.
ECIEPI201834035A 2015-11-05 2018-05-03 Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico ECSP18034035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (en) 2015-11-05 2016-11-03 Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
ECSP18034035A true ECSP18034035A (es) 2018-05-31

Family

ID=54476881

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201834035A ECSP18034035A (es) 2015-11-05 2018-05-03 Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico

Country Status (35)

Country Link
US (2) US10941139B2 (es)
EP (1) EP3371179B1 (es)
JP (1) JP6929292B2 (es)
KR (1) KR20180073678A (es)
CN (1) CN108349960B (es)
AR (1) AR106604A1 (es)
AU (1) AU2016347724B2 (es)
CA (1) CA3003085A1 (es)
CL (1) CL2018001210A1 (es)
CO (1) CO2018004581A2 (es)
CR (1) CR20180256A (es)
CY (1) CY1122441T1 (es)
DK (1) DK3371179T3 (es)
EA (1) EA035625B1 (es)
EC (1) ECSP18034035A (es)
ES (1) ES2755101T3 (es)
HK (1) HK1256754B (es)
HR (1) HRP20191729T1 (es)
HU (1) HUE046033T2 (es)
IL (1) IL259067B (es)
LT (1) LT3371179T (es)
MA (1) MA43160B1 (es)
MX (1) MX2018005379A (es)
MY (1) MY189448A (es)
PH (1) PH12018500852B1 (es)
PL (1) PL3371179T3 (es)
PT (1) PT3371179T (es)
RS (1) RS59498B1 (es)
SG (1) SG11201803181SA (es)
SI (1) SI3371179T1 (es)
TN (1) TN2018000131A1 (es)
TW (1) TWI714661B (es)
UY (1) UY36979A (es)
WO (1) WO2017076998A1 (es)
ZA (1) ZA201802322B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN110831633A (zh) * 2017-05-10 2020-02-21 赛诺菲 可用于治疗的肽类接头和念珠藻素缀合物及其制备
CN108107103B (zh) * 2017-12-14 2020-10-16 华中师范大学 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法
CA3132613A1 (en) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
US11530204B2 (en) 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017093A1 (en) * 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins
US20020128185A1 (en) * 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EP2044122B1 (en) 2006-07-18 2018-03-28 Sanofi Antagonist antibody against epha2 for the treatment of cancer
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途

Also Published As

Publication number Publication date
AU2016347724B2 (en) 2021-04-01
IL259067B (en) 2021-07-29
CO2018004581A2 (es) 2018-07-19
PT3371179T (pt) 2019-11-18
TW201730164A (zh) 2017-09-01
HUE046033T2 (hu) 2020-01-28
SI3371179T1 (sl) 2019-11-29
MX2018005379A (es) 2018-09-05
NZ741734A (en) 2023-10-27
RS59498B1 (sr) 2019-12-31
TN2018000131A1 (en) 2019-10-04
MY189448A (en) 2022-02-14
EA035625B1 (ru) 2020-07-17
CL2018001210A1 (es) 2018-08-17
JP2018535255A (ja) 2018-11-29
PL3371179T3 (pl) 2020-02-28
CN108349960A (zh) 2018-07-31
US20190382391A1 (en) 2019-12-19
CY1122441T1 (el) 2021-01-27
HK1256754B (zh) 2020-06-05
CN108349960B (zh) 2022-05-27
CA3003085A1 (en) 2017-05-11
WO2017076998A1 (en) 2017-05-11
SG11201803181SA (en) 2018-05-30
EP3371179A1 (en) 2018-09-12
US10941139B2 (en) 2021-03-09
ZA201802322B (en) 2019-01-30
TWI714661B (zh) 2021-01-01
UY36979A (es) 2017-06-30
HRP20191729T1 (hr) 2019-12-13
LT3371179T (lt) 2019-11-11
US20210163458A1 (en) 2021-06-03
AR106604A1 (es) 2018-01-31
JP6929292B2 (ja) 2021-09-01
BR112018008490A2 (pt) 2019-02-12
DK3371179T3 (da) 2019-11-11
PH12018500852A1 (en) 2018-10-29
EA201890898A1 (ru) 2018-10-31
CR20180256A (es) 2018-08-13
EP3371179B1 (en) 2019-08-07
MA43160B1 (fr) 2019-12-31
PH12018500852B1 (en) 2018-10-29
KR20180073678A (ko) 2018-07-02
ES2755101T3 (es) 2020-04-21
AU2016347724A1 (en) 2018-05-10
IL259067A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
ECSP18034035A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
AR091837A1 (es) Compuestos para inmunoterapia dirigida
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
GT201400111A (es) Triazolopiridinas sustituidas
UY36702A (es) Piridinas sustituidas y métodos de uso
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
UY35922A (es) Derivados de sulfonamidas tricíclicas
CO6321288A2 (es) Sales de compuestos inhibidores de vih
UY37348A (es) Agentes antibacterianos de 2-pirrolidin fenilhidrazidas
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
UY38217A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona